Literature DB >> 6355132

High-performance liquid chromatographic preparation of single-site carrier-free pancreatic polypeptide hormone radiotracers.

B H Frank, M J Beckage, K A Willey.   

Abstract

The preferred radiotracer for use in radioimmuno- and receptor assays is one which is as similar as possible to the native hormone in both physicochemical and biological properties. Until recently, rapid detailed evaluation of iodination methodology as well as separation of site-specific tracers and their evaluation relative to the native protein has not been possible. Using reversed-phase high-performance liquid chromatographic methodology (C8 or C18 columns) we have evaluated a variety of iodination techniques and conditions. Procedures were found that allow the isolation of site-specific radiolabelled protein hormones in a rapid, reproducible and quantitative manner. The radiotracers are of the highest possible specific activity, have very low levels of damage and are more stable than tracers prepared by conventional techniques. This methodology has been applied to preparing tracers of beef, pork and human insulins, proinsulins and C-peptides as well as analogues of these proteins. In addition, the methodology has been applied to somatostatin, glucagon, pancreatic polypeptide, vasoactive intestinal peptide and luteinizing hormone-releasing hormone. The use of these tracers yielded increased sensitivity and reproducibility in a number of radioimmunoassays (e.g. C-peptide and glucagon), more reproducible results in radioreceptor assays (e.g. insulin receptors) and more defined studies on drug absorption and degradation. Finally, scale-up of our isolation procedures has yielded the 127I-analogue for homologous binding and displacement studies.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6355132     DOI: 10.1016/s0021-9673(01)90897-0

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  High affinity binding sites for proinsulin in human IM-9 lymphoblasts.

Authors:  P M Jehle; M P Lutz; R D Fussgaenger
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

2.  Conversion of biosynthetic human proinsulin to partially cleaved intermediates by collagenase proteinases adsorbed to isolated rat adipocytes.

Authors:  W C Duckworth; D E Peavy; F G Hamel; J Liepnieks; M R Brunner; R E Heiney; B H Frank
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

3.  Different binding and degradation of proinsulin, insulin and insulin-like growth factor-1 (IGF-1) in cultured renal proximal tubular cells. Implications for the prolonged serum half-life of proinsulin.

Authors:  P M Jehle; R D Fussgänger; S Stracke; R W Grunewald; F Keller
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

4.  In vitro activity of biosynthetic human diarginylinsulin.

Authors:  S Zeuzem; E Stahl; E Jungmann; M Zoltobrocki; K Schöffling; W F Caspary
Journal:  Diabetologia       Date:  1990-02       Impact factor: 10.122

5.  Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects.

Authors:  C Bogardus; S Lillioja; B V Howard; G Reaven; D Mott
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

6.  Metabolism and placental transfer of 125I-proinsulin and 125I-tyrosylated C-peptide in the pregnant rhesus monkey.

Authors:  P A Gruppuso; J B Susa; P Sehgal; B Frank; R Schwartz
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

7.  Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme.

Authors:  Marika Manolopoulou; Qing Guo; Enrico Malito; Alexander B Schilling; Wei-Jen Tang
Journal:  J Biol Chem       Date:  2009-03-25       Impact factor: 5.157

8.  Characterization of specific pancreatic polypeptide receptors on basolateral membranes of the canine small intestine.

Authors:  W R Gilbert; B H Frank; J R Gavin; R L Gingerich
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.